about
Eradication of factor VIII inhibitors in patients with mild and moderate hemophilia ASequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors.Bivalirudin for anticoagulation in children.FondaKIDS: a prospective pharmacokinetic and safety study of fondaparinux in children between 1 and 18 years of age.Argatroban therapy in pediatric patients requiring nonheparin anticoagulation: an open-label, safety, efficacy, and pharmacokinetic study.Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children: a systematic review and meta-analysis of observational studies.Rofecoxib as adjunctive therapy for haemophilic arthropathy.New approaches in the management of inhibitor patients.Celecoxib in the treatment of haemophilic synovitis, target joints, and pain in adults and children with haemophilia.Impact of inherited thrombophilia on venous thromboembolism in children: a systematic review and meta-analysis of observational studies.Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review.New anticoagulants in children: a review of recent studies and a look to the future.When should prophylaxis therapy in inhibitor patients be considered?Old and new antithrombotic drugs in neonates and infants.How I treat pediatric venous thromboembolism.Difficult clinical challenges in haemophilia: international experiential perspectives.From boy to man: recommendations for the transition process in haemophilia.Off-label use of rFVIIa in children with excessive bleeding: a consecutive study of 153 off-label uses in 139 children.Comparison of kaolin and tissue factor activated thromboelastography in haemophilia.Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography.Standardization of thromboelastography: a report from the TEG-ROTEM working group.A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors.Radionuclide synovectomy/synoviorthesis (RS) in persons with bleeding disorders: A review of impact of national guidance on frequency of RS using the ATHNdataset.Chromogenic analysis of FIX activity in haemophilia B patients treated with nonacog beta pegol.Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison.Patient/caregiver-reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE).Patient- and caregiver-reported bleeding symptoms and reasons for starting and stopping treatment with recombinant factor VIIa: analysis of the Dosing Observational Study in Haemophilia (DOSE).Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors.Clinical manifestations of the prothrombin G20210A mutation in children: a pediatric coagulation consortium study.Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B.Defining extended half-life rFVIII-A critical review of the evidence.Implementing emicizumab in hemophilia inhibitor management: emicizumab should be prescribed after toleranceThromboelastography and thrombin generation assay in inherited afibrinogenemiaCatheter-directed thrombolysis in a child with acute lymphoblastic leukemia and extensive deep vein thrombosisEffect of anticoagulation on the occurrence of deep venous thrombosis associated with temporary transvenous femoral pacemakersCoagulation abnormalities in the carbohydrate-deficient glycoprotein syndrome: case report and review of the literatureProthrombin G20210A mutation in a child with spinal cord infarctionPilot dose-finding and safety study of bivalirudin in infants <6 months of age with thrombosisPediatric catheterization laboratory anticoagulation with bivalirudinPharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII
P50
Q30539581-1D1335A1-EEA1-464D-82B6-22ADC7F3F2E9Q33361533-4A0FC295-DF3A-4038-A1A3-8384D4CEFD82Q33381296-B5C19748-7F0E-46E8-A7FA-51F753C75D8DQ33394131-7BD343EF-FB9B-4655-BA27-D1227BD8829EQ33394891-59E1B314-0C0D-442A-9EAC-3866A4596CE5Q33553076-25A22058-BCA0-4D81-A91D-B655DF1DB0A6Q36117538-53459FF0-7235-4871-9112-81BBCAC58BA6Q36426640-1F31FF83-F4B2-4BC0-A217-0AB938759D12Q36570899-2002614F-F176-4124-B853-E0E830CB8F40Q37263729-AA3E9DB8-A51A-4926-A07E-7AA78C6BC129Q37719683-2AFD18DC-EC33-4FC0-A3E2-475BDB829A14Q37815638-0E24C142-08B9-4527-8089-31E94635197AQ37854874-554C81A3-E4AF-4A4E-89A2-212F83DCC0BBQ37911711-9217DB96-7536-4CC6-BAD2-6F600EE275F5Q38642481-0964296A-D78C-42C3-916D-70296A7FC18DQ42656818-081BD566-27C2-4582-A0A2-82F3BD078B62Q44933182-EF2F7A51-C116-4CB8-9539-4C3AFD33FBCBQ45841697-A420FAB9-C746-4714-A634-B4222A0C724FQ45855896-C67655AD-4248-43B0-AB29-AB104D468CFAQ45863543-0A74944F-8E87-4FAA-A27B-C1AC96D7FE50Q45867256-71499540-2938-4150-898A-42116CADCF79Q45868043-D7FAB2C1-2BB2-47B1-9037-A0BF7749C4FAQ45868186-3B0DCEAE-8491-409E-BE12-17044E64AD87Q45872102-D1E9C002-1CA1-451F-B092-2B8758F01FD9Q45873703-14E67DB0-FA68-443B-AAAD-B7CB22CA34DCQ45875884-EF21C7C2-18D1-4794-8A29-F3B3ACAD1C34Q45877257-F79E0BD5-7FF0-4963-A3CB-48C388BB4031Q45883290-28E5897E-B22F-45C9-9AF2-4E3863F6B1C8Q46876638-2EACCE2A-B548-4FA0-9C13-961A5067F382Q48099558-99F1E608-F0AB-42B8-9493-7B23C61A9538Q52597091-EF734C9D-8BEB-4DEC-9536-74FE8E24BE47Q57795848-B2515831-DE36-4CF3-A96F-356AB878077BQ57806521-CA6165AE-94D5-4766-8A93-AED0AED9B3B2Q73496187-C5E5008B-A957-42AE-8CB6-1A182454D350Q74598923-D38E59D2-86AE-40C9-A88B-CC317CBC4C28Q77779053-C98ED142-9B0F-4B76-BD1E-0BFC62769CC4Q77835274-F0D61990-3611-40CC-B2A3-412EBB775851Q80702669-5684D21B-490C-4BDD-BF14-C3374DC7526AQ83699342-9E455A9C-2643-4A9E-847F-4782D733797BQ88586127-D31FB940-1EAC-419C-80FE-1C0BFF18DADE
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Guy Young
@ast
Guy Young
@en
Guy Young
@es
Guy Young
@nl
Guy Young
@sl
type
label
Guy Young
@ast
Guy Young
@en
Guy Young
@es
Guy Young
@nl
Guy Young
@sl
prefLabel
Guy Young
@ast
Guy Young
@en
Guy Young
@es
Guy Young
@nl
Guy Young
@sl
P1053
I-1880-2012
P106
P21
P31
P3829
P496
0000-0001-6013-1254